Cargando…

Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163717/
https://www.ncbi.nlm.nih.gov/pubmed/35669569
http://dx.doi.org/10.1177/17588359221104274